HumanITCare welcomes former Sanofi Anna Arcos as new partner

Experienced Global Financial Director Joins French Pharmaceutical Company's Board of Directors

HumanITcare adds new partners. The Spanish company specializing in digital medicine welcomes Anna Arcos, a professional known for her time at one of the Sanofi pharmaceutical companies, into its capital, according to Núria Pastor, co-founder and CEO of HumanITcare, to PlantaDoce.

Arcos acquires a minority stake in HumanITcare, which remains majority controlled by the founding team. The board of directors has worked for the French multinational Sanofi for eight years,  her last position being global financial director in the  consumer healthcare area , managing a team of more than eighty employees. At Sanofi, Arcos was also responsible for finance of the general medicine division in Eurasia and the Middle East, as well as vice president of internal audit of the French pharmaceutical group.

Prior to Sanofi, Arcos worked in consulting at PwC; in the energy services industry, in the former Schlumberger, or in the technology sector, in the American Itron, among other companies. HumanITcare is a technology company in the telemedicine sector. Through its  medical software solution  , it allows hospitals, insurers and clinics to have a tool to remotely monitor  patients and anticipate possible relapses.

The HumanITcare system is made up of a medical portal that can be integrated into medical records  where the health of patients is viewed remotely, and an  app , where patients monitor their vital signs, and can make use of the video call or chat service. The system is present in more than twenty hospitals and different countries.

Recently, HumanITcare has closed a collaboration agreement with Clínicas MI  to accompany cancer patients throughout their treatment, from any location, 24 hours a day, 365 days a year. The tool allows for personalized monitoring, using artificial intelligence, facilitating comprehensive support by the professional and improving the patient's quality of life. By monitoring a series of vital indicators, the doctor can thus anticipate the doubts, concerns and needs of such a delicate patient, and who suffers from so much uncertainty, such as cancer patients.

 The agreement, for an initial duration of three years, contemplates an exclusivity clause in oncology and Catalan territory according to which only Clínicas Mi centers will be able to offer this service for monitoring cancer patients. The service has been inaugurated at the Mi Tres Torres clinic in Barcelona, but, after the positive results experienced in the Catalan capital, it is foreseeable that the solution will begin to be implemented in Mi NovAliança (Lleida) throughout this quarter.

Published on : 23rd June, 2023